- The clinical-stage immuno-oncology company, Agenus ( NASDAQ: AGEN ) jumped more than 20% on Tuesday to record the best intraday rise since May 2021 on above average volumes.
- More than 5.4M Agenus ( AGEN ) shares have changed hands so far, compared to the 65-day average volume of ~4.8M.
- Noting a recent data readout for a combination therapy involving its PD-1 inhibitor balstilimab in colorectal cancer, Seeking Alpha contributor Avisol Capital Partners argued on Monday that the company “looks to be on a much more solid footing.”
- In October, Agenus ( AGEN ) said it would withdraw the marketing application for balstilimab on FDA advice.
- The regulator noted that the Biologics License Application was no longer considered for a review under accelerated approval only four months after the full approval of Keytruda (pembrolizumab).
- Citing a single-arm trial of 140 patients, Agenus ( AGEN ) said at the time that balstilimab demonstrated an objective response rate (ORR) of 20% and 8% compared to 14% and 0% ORR for pembrolizumab in PD-L1 positive and negative cancer patients, respectively.
For further details see:
Agenus rallies 20% to post best intraday in over 13 months